Related Experiment Video
Updated: Jul 16, 2026

Implantation of the Syncardia Total Artificial Heart
Published on: July 18, 2014
Heart Transplantation Requiring Permanent Pacemaker: Risk Factors and Outcomes
Michael Keller1, Ye In Christopher Kwon1, Yashar Haghighi1
1Division of Cardiothoracic Surgery, Department of Surgery, Pauley Heart Center, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA.
Insights
Permanent pacemaker (PPM) implantation after heart transplantation (HT) is not linked to increased mortality. Early PPM showed lower graft failure and primary graft dysfunction, while late PPM had short-term survival impacts but not long-term.
Area of Science:
- Cardiology
- Transplantation Medicine
- Medical Devices
Background:
- A subset of heart transplant recipients require permanent pacemakers (PPM).
- Understanding risk factors and outcomes for PPM implantation post-heart transplantation (HT) is crucial.
Purpose of the Study:
- To explore risk factors and outcomes associated with early (pre-discharge) and late (>6 months post-transplant) PPM implantation in adult HT recipients.
- To assess the impact of PPM implantation on recipient survival and graft function.
Main Methods:
- Utilized the United Network for Organ Sharing (UNOS) database (2013-2023) for adult HT patients receiving early or late PPM.
- Employed propensity score matching (PSM) for control cohorts.
- Analyzed recipient survival, graft failure, primary graft dysfunction (PGD), and mortality using Cox and logistic regression, and Kaplan-Meier curves.
Main Results:
- Early PPM recipients (n=354) demonstrated similar survival but lower graft failure and PGD rates compared to controls.
- Late PPM recipients (n=554) showed reduced short-term survival (30 days, 1 year) but not at 5 years.
- Neither early nor late PPM independently increased mortality risk post-HT; Donation after Circulatory Death (DCD) organs correlated with lower early PPM risk.
Conclusions:
- Permanent pacemaker implantation, whether early or late, is not an independent predictor of mortality following heart transplantation.
- Distinct short-term morbidity and mortality profiles exist between early and late PPM implantation groups.
- Further investigation into the specific mechanisms driving these observed differences is warranted.
Abstract:
Background/Objectives: Following heart transplantation (HT), a subset of patients will require an early or late permanent pacemaker (PPM). We explored risk factors and outcomes associated with PPM implantation in this population. Methods: Using the United Network for Organ Sharing (UNOS) database, we identified all adult patients undergoing HT from 2013 to 2023 who received a PPM early (prior to discharge) or late (>6 months post transplant). Propensity score matching (PSM) was used for control cohorts was. Primary outcomes included recipient survival at 30 days and 1 and 5 years. Predictors of early and late PPM, as well as post-PPM mortality, were assessed using Cox and logistic regression models. Kaplan-Meier survival curves were compared using a log-rank test. Results: Following PSM, the early PPM cohort included 354 patients, and the late PPM cohort included 554 patients. Early PPM patients showed similar 30-day and 1- and 5-year survival (p = 0.582, 0.421, and 0.2844 respectively) but lower rates of graft failure (1.1% vs. 4%, p = 0.017) and primary graft dysfunction (PGD) (1.7% vs. 4.2%, p = 0.046). Late PPM patients had reduced survival at 30 days and 1 year but not at 5 years (p < 0.001, p = 0.0023, 0.050 respectively). Neither early nor late PPM was independently associated with increased risk of mortality after HT. Donation after Circulatory Death (DCD) organs were associated with a lower risk of early PPM (aOR = 0.409, p = 0.020). Late PPM patients showed higher rates of PGD (2.5% vs. 0.5%, p = 0.007). Conclusions: Early or late PPM is not an independent risk factor for mortality after HT, but differing short-term morbidity and mortality are observed.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy

